FibroGen (FGEN) Tops Q3 EPS by 55c; Reports Cash and Cash Equivalents of $665.0M

FibroGen (NASDAQ: FGEN) reported Q3 EPS of $0.54, $0.55 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $156 million versus the consensus estimate of $143.46 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• BlackRock’s Rosenberg says inflation data key after jobs beat
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)